openPR Logo
Press release

PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027

04-07-2017 11:56 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

PARP Inhibitors Market Dynamics, Segments, Size and Demand,

Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors used to treat subset of ovarian cancer. Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP inhibitors mainly indicated in few set of patients based molecular diagnostics. Several positive end points for these drugs are prolonged Progression Free Survival (PFS) and over survival rates.

PARP inhibitors Market: Drivers and Restraints

PARP inhibitors market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients. Apart from aforementioned drivers, PARP inhibitors market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period.

PARP inhibitors market hindered by the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and stringent regulatory requirement for the approvals of the PARP inhibitors over the forecast period. In addition, development of PARP inhibitors have been full of up and down and late stage recall of few developmental drugs expected to hinder the market revenue growth of PARP inhibitors over the forecast period.

Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3197

PARP inhibitors Market: Segmentation

PARP inhibitors market has been segmented on the basis of drug type, indication, distribution channel and Region.

Based on the drug type, the PARP inhibitors market is segmented into the following:

Lynparza

Niraparib

Rucaparib

Talazoparib

Veliparib

Based on the indication, the PARP inhibitors market is segmented into the following:

Ovarian Cancer

Breast Cancer

Prostate Cancer

Pancreatic Cancer

Based on the distribution channel, the PARP inhibitors market is segmented into the following:

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3197

PARP inhibitors Market: Overview

PARP inhibitors market is witnessing significant changes due to increasing opportunity owing to rush of big Pharma companies to buy the drug discovery companies like Tesaro and Clovis who’s pipeline PARP inhibitors shown positive results. Companies like Pfizer continuously looking for investing in the companies having product pipeline of PARP inhibitors. PARP inhibitors market is highly competitive as several small and large Pharma companies are having presence in the segment with promising pipeline products or marketed products.

PARP inhibitors Market: Region-wise Outlook

Geographically, PARP inhibitors market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key market for PARP inhibitors market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalPARP inhibitors market by the regions over the forecast period. Asia Pacific PARP inhibitors market is anticipated to present lower growth opportunity owing to lack of regulatory protection for innovative drugs and reimbursement policies in the region.

PARP inhibitors Market: Key Players

Some of the players in the global PARP inhibitors market are AstraZeneca, AbbVie, Clovis Oncology, Medivation and Tesaro to name a few.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Press: press@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027 here

News-ID: 494797 • Views: 231

More Releases from Future Market Insights

Hormone Replacement Therapy Market COVID-19 Impact and Global Analysis by Produc …
Hormone Replacement Therapy is any form of hormone therapy where in the patient, in course of medical treatment, receives hormones, either to supplement a lack of naturally occurring hormones, or to substitute other hormones for naturally occurring hormones. Menopause, is the time in most women's lives when menstrual periods stop permanently, and the woman is no longer able to have children. Menopause typically occurs between 45 and 55 years of age.
Critical Care Information Systems Market Key Players- Affiliated Computer Servic …
Critical care information systems are used to help manage the large amount of data generated in an intensive care unit every day. Obtaining, synchronizing, assimilating, and evaluating patient data is very difficult because of incompatibilities among monitoring equipment, the absence of standard data formatting and proprietary limitations from industry. The intensive care units are a specialized section of a hospital containing the equipment, medical and nursing staff, monitoring and life
Paper Cores Demand Catalyzes amid High Emphasis on Circular Economy: FMI Study
The global packaging industry has made remarkable progress in recent years, with numerous innovations and technological advances prioritized. Particular emphasis is placed on ensuring sustainability and the spread of the circular economy. Reliable benefits have been obtained in reducing the generation of municipal solid waste. Future Market Insights is a recently published research report that incorporates historical analysis from 2015 to 2019 and future assessments from 2020 to 2030 to
Endometrial Cancer Treatment Market Key Players- R-Pharm-US LLC., Bristol-Myers …
Endometrial cancer or uterine cancer is one of the most common gynecological cancers and 2.8% of women are diagnosed with the endometrial cancer at some point in their lives. According to National Cancer Institute statistics, in 2015 endometrial cancer contributed to 1.8% of all cancers and 3.6% of all new cancer cases were diagnosed as endometrial cancer. Early detection of endometrial cancer helps in the selection of proper treatment options.

All 5 Releases


More Releases for PARP

PARP Inhibitors Market Size (Value & Volume), Future Trends, Opportunities and S …
"PARP Inhibitors Market: Global Industry Analysis and Opportunity Assessment 2017-2027" is the latest addition to MarketResearchReports.Biz industry research reports collection. The main objective of this report is to aid the user in understanding the market “PARP Inhibitors Market ” as a whole, its definitions, segmentation, market potential, influential trends, and the barriers that it is facing. Meticulous research and analysis were an important part of the report preparation. Those reading the
PARP Inhibitors Market Size, Current Trends, Challenges, Dynamics, Technology an …
"The Latest Research Report PARP Inhibitors Market: Global Industry Analysis and Opportunity Assessment 2017-2027 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz” Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
Global PARP Inhibitor Market Analysis, Size, Trends and Forecasts (2016-2020)
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. The report analyses the global Lynparza market in detail along with the regional analysis as it is the
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. The report analyses the global Lynparza market in detail along with the regional analysis as
02-01-2010 | Sports
Trevigen, Inc.
HT PARP in vivo Pharmacodynamic Assay II
Trevigen announces a validated assay, with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening. Pharmacodynamic (PD) assays have recently been developed and employed early in the drug screening process to assess the ability of potential drug candidates to affect molecular targets. These assays have the advantages of performing molecular proof-of-concept investigations at an early stage such as